1 October 1991 The myelodysplastic syndromes (MDS) represent a morphologically distinct group of pre-leukaemic conditions. They are relatively common among haematological malignancies. The age specific incidence rate is 3 60/100 000 population with a relative risk of 102 5 in Leicestershire' (range 80 to 120).' Forty per cent of patients with MDS may progress over months into acute myeloid leukaemia (AML). Serial studies into the pathogenesis have been made on such patients. The syndromes are well recognised on morphological grounds, but little is known about the aetiology.
Chromosomal abnormalities are present in both MDS and AML and carry a variable prognosis.' Proto-oncogenes are genes which control normal cellular proliferation and differentiation. Genetic alteration in their structure or regulation results in oncogene activation, disordered control, and neoplasia. However, altered expression may arise from the disease state rather than direct genetic mutation. In AML N-ras and c-myc may be activated by point mutation, gene amplification, or translocation.3 C-myb, c-mos, c-erb Bl, c-fos and cets are also increased in expression.4 N-ras oncogene point mutations occur in up to 40% of cases with MDS' and loss of the mutant form may accompany clinical remission. 6 But the role of c-myc, c-myb, and other oncogenes found in both MDS and AML is not clear." 4 We therefore investigated a cohort of 130 patients over two years and studied pathogenesis at the chromosomal and molecular level to ascertain if there was any correlation with specific oncogene activation. (table 1) were excised from the recombinant sequences by restriction endonuclease digestion and were 32P labelled using the method outlined by Feinberg and Volgelstein." The RNA membranes were hybridised using methods previously described by Grosso and Pitot"2 and hybridisation was detected by autoradiography at -70°C with an intensifying screen. (Dupont Cronex) using preflashed X-OMAT AR film (Kodak). The level or intensity of the slot was quantified by densitometry using a laser scanning densitometer (Pharmcia/LKB)."3
Methods
The probes were initially evaluated using total RNA from the cell line HL60 to establish the required stringency for specific Table 5 shows the relative expressions of the four oncogenes which were significantly raised in this third group ofpatients. C-myc, c-ets, and c-fos were increased in both disorders; increased c-abl expression occurred in iron deficiency anaemia alone. Survival curves were plotted using life table survival estimates and differences between groups assessed by logrank tests. The median survival for RA, SA, and CMML had not been reached by two years. That for RAEB and RAEBT was 12 months (p = 0 0007). Trisomy 8 conferred a survival advantage in RA, SA, and CMML, but not in RA progressing to RAEBT (p = 0-7). Similarly, a c-mos expression of >0 6 at presentation in these three subgroups suggested a trend towards longer survival (figure).
Discussion
Unlike chronic myeloid leukaemia (CML), characterised by the Philadelphia chromosome and bcr/abl fusion oncogene, no one specific chromosomal abnormality or oncogene activation is pathognomonic for the myelodysplastic syndrome. In our study c-myc, c-myb, c-mos, cabl and c-ets expressions were increased and increased with progression of each disorder. 
